Orum Secures 145 Billion KRW Funding to Accelerate DAC Programs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: Newsfilter
- Funding Support: Orum Therapeutics has successfully secured 145 billion KRW (approximately $100 million) in convertible preferred stock investments, primarily led by KB Investment, signaling strong confidence from investors in its scientific direction and establishing a solid foundation for the company's next growth phase.
- Program Advancement: This funding will support the clinical evaluation of ORM-1153 and additional programs, propelling Orum's innovations in oncology and other serious diseases, thereby reinforcing its leadership position in next-generation DACs.
- Infrastructure Expansion: The capital will be utilized to expand Orum's scientific and operational infrastructure, enhancing its capabilities in DAC projects based on selectivity, potency, and rational payload design, which will strengthen its competitive edge in the market.
- Investor Confidence: New investors, including Boston-based Weiss Asset Management and Korea Investment Partners, demonstrate recognition of Orum's long-term potential in biotechnology, further enhancing its operational capabilities in the global market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KB
About KB
KB Financial Group Inc is a Korean-based company principally engaged in the financial business. The Company operates its business through six segments. The Banking segment consists of retail banking services provided by Kookmin Bank. This segment is engaged in the lending and receiving of large corporations, small and medium-sized businesses, SOHO and household customers, the investment of securities and derivatives, and financing, among others. The Credit Card segment operates credit sales, cash advances and card loans, among others. The Securities segment is engaged in the trading, consignment and acquisition of securities. The Non-life Insurance segment is engaged in the non-life insurance. The Life Insurance segment is engaged in the life insurance. The other segment is engaged in the maintenance of computer-related equipment and systems, the investigation of credit and the collection of debt, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VEU ETF Hits 52-Week High of $75.895, Last Trade at $75.31
- Price Fluctuation Analysis: The VEU ETF has a 52-week low of $53.65 and a high of $75.895, with the last trade at $75.31, indicating significant volatility over the past year that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide investors with valuable insights for technical analysis, helping them assess market trends and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors are actually buying and selling 'units' that can be created or destroyed based on investor demand, thereby impacting the underlying asset holdings and overall market liquidity.
- Inflows and Outflows Monitoring: Weekly monitoring of the week-over-week change in shares outstanding helps identify ETFs experiencing notable inflows or outflows, which can directly affect the individual components held within these ETFs.
Continue Reading
NASDAQ 100 After Hours Trading Highlights Active Stocks
- Volume Overview: The NASDAQ 100 After Hours Indicator fell by 3.57 points to 25,521.99, with a total after-hours volume of 89,566,039 shares traded, indicating a shift in market activity that could influence short-term investor decisions.
- Stock Performance: Lineage, Inc. (LINE) remained unchanged at $34.34 with 4,137,960 shares traded, reflecting a cautious market sentiment as its current price is 85.85% of the target price.
- Recommendation Ratings: Genius Sports Limited (GENI) decreased by 0.2 to $10.74 with 4,112,963 shares traded, and Zacks reports its current mean recommendation is in the
Continue Reading